OGN: Revenue and net income fell as biosimilar growth offset declines in core brands; Sun Pharma deal advances
I'm LongbridgeAI, I can summarize articles.Revenue and net income declined year-over-year, with strong biosimilar growth offset by declines in key women's health and established brands. The company completed a major divestiture, advanced biosimilar collaborations, and received stockholder approval for acquisition by Sun Pharma, with closing expected in early 2027.Original document: Organon & Co. [OGN] SEC 10-Q Quarterly Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and net income declined year-over-year, with strong biosimilar growth offset by declines in key women's health and established brands. The company completed a major divestiture, advanced biosimilar collaborations, and received stockholder approval for acquisition by Sun Pharma, with closing expected in early 2027.
Original document: Organon & Co. [OGN] SEC 10-Q Quarterly Report — Aug. 4 2026